The Oslo Medicines Initiative: a new social contract with pharma
EPHA #A2MDialogues WATCH THE DISCUSSION
15 June 2021
13:00-14:00 CEST
online
Continuing our successful online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
The Oslo Medicines Initiative: Better access to effective, novel, high-priced medicines – a new vision for collaboration between the public and private sectors is a new initiative of the WHO Regional Office for Europe, developed together with the Norwegian Ministry of Health and Care Services and the Norwegian Medicines Agency.
The Initiative aims to provide a neutral platform for the public and private sectors to jointly outline a vision for equitable and sustainable access to effective, innovative and affordable medicines.
Join us to discuss why a new social contract is needed to build an environment of mutual trust and cooperation between the pharmaceutical industry, governments and patients.
#A2MDialogues
Panelists
Dr Natasha Azzopardi-Muscat
Director of the Division of Country Health Policies and Systems
WHO European Region
Dr Audun Haga
Director General
Norwegian Medicines Agency
Jo de Cock
CEO
National Institute of Health and Disability Insurance (NIHDI), Belgium
Moderator
Yannis Natsis
Policy Manager, Universal Access and Affordable Medicines
European Public Health Alliance
Catch up on EPHA’s other #A2MDialogues below
Negotiating with pharma: lessons from the EU COVID-19 vaccine negotiations
12:00-13:00 CEST | 18 May 2021
Sustainable access to effective antibiotics - what should the EU do?
15 April 2021
After COVID-19, what's next for EU medicines policies?
9 March 2021
Getting it right: Recommendations for a European BARDA
8 December 2020
The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
Pharma & COVID19: Winners, losers, prospects
19 November 2020
The EU's IP strategy: Enabler or barrier?
27 October 2020
Unleashing meaningful innovation through regulatory reform
19 October 2020
